Protective Effect of Val129-PrP against Bovine Spongiform Encephalopathy but not Variant Creutzfeldt-Jakob Disease
Natalia Fernández-Borges
1, Juan Carlos Espinosa
1, Alba Marín-Moreno, Patricia Aguilar-Calvo, Emmanuel A. Asante, Tetsuyuki Kitamoto, Shirou Mohri, Olivier Andréoletti, and Juan María Torres
Author affiliations: Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (CISA-INIA); Valdeolmos, Madrid, Spain (N. Fernández-Borges, J.C. Espinosa, A. Marín-Moreno, P. Aguilar-Calvo, J.M. Torres); MRC Prion Unit, Department of Neurodegenerative Disease, University College London, Institute of Neurology, London, UK (E.A. Asante); Tohoku University Graduate School of Medicine, Sendai, Japan (T. Kitamoto, S. Mohri); UMR INRA ENVT 1225, Interactions Hôtes Agents Pathogènes, Ecole Nationale Vétérinaire de Toulouse, Toulouse, France (O. Andréoletti)
Main Article
Table 2
Transmission of cattle, porcine, sheep, and goat BSE isolates to mice in transgenic mouse lines TgMet129, TgMet/Val129, and TgVal129*
Isolates
|
Mean survival time, d ±SD (no. PrPres-positive/inoculated animals) [reference]†‡ |
TgMet129
|
|
TgMet/Val129
|
|
TgVal129
|
First passage
|
Second passage
|
First passage
|
Second passage
|
First passage
|
Second passage
|
Hu-sCJD MM1 |
219 ±17 (6/6) [40] |
239 ±8 (6/6) [40] |
|
243 ±14 (6/6) [40] |
260 ±13 (6/6) [40] |
|
327 ±19 (6/6) [40] |
286 ±16 (6/6) [40] |
Hu-sCJD VV2 |
618 ±81 (6/6) [40] |
509 ±41 (6/6) [40] |
|
588 ±74 (6/6) [40] |
594 ±86 (6/6) [40] |
|
168 ±12 (6/6) [40] |
169 ±12 (6/6) [40] |
Hu-TSE negative |
>700‡ (0/6) |
>700‡ (0/6) |
|
>700‡ (0/6) |
>700‡ (0/6) |
|
>700‡ (0/6) |
>700‡ (0/6) |
Ca-BSE0 |
739 (1/6) (31) |
633 ±32 (6/6) |
|
>700‡ (0/6) |
>700‡ (0/6) |
|
>700‡ (0/6) |
>700‡ (0/6) |
Ca-BSE2 |
491–707 (0/9) [31] |
572 ±37 (3/4) [31] |
|
>700‡ (0/5) |
ND |
|
>700‡ (0/3)§ |
>700‡ (0/3)§ |
Ca-BSE/TgPo |
653 ±45 (3/5) |
ND |
|
ND |
ND |
|
>700‡ (0/6) |
ND |
Ca-BSE/Sh(ARQ) |
615 ±84 (4/6) [31] |
564 ±39 (5/5) [31] |
|
>700b (0/6) |
>700‡ (0/6) |
|
>700‡ (0/6) |
>700‡ (0/6) |
Ca-BSE/Go |
>700‡ (5/5) |
>700‡ (5/5) |
|
476 (1/10) |
ND |
|
>700‡ (0/5)¶ |
ND |
Go-BSE |
683 ± 36 (6/6) |
675 ± 36 (5/5) |
|
>700‡ (0/6) |
ND |
|
>700‡ (0/6) |
ND |
Main Article
References
Collinge J,
Sidle KC,
Meads J,
Ironside J,
Hill AF.
Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature.
1996;
383:
685–
90.
DOIPubMed Hill AF,
Desbruslais M,
Joiner S,
Sidle KC,
Gowland I,
Collinge J,
et al. The same prion strain causes vCJD and BSE. Nature.
1997;
389:
448–
50, 526.
DOIPubMed Bruce ME,
Will RG,
Ironside JW,
McConnell I,
Drummond D,
Suttie A,
et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature.
1997;
389:
498–
501.
DOIPubMed Llewelyn CA,
Hewitt PE,
Knight RS,
Amar K,
Cousens S,
Mackenzie J,
et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet.
2004;
363:
417–
21.
DOIPubMed Peden AH,
Head MW,
Ritchie DL,
Bell JE,
Ironside JW.
Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet.
2004;
364:
527–
9.
DOIPubMed Wroe SJ,
Pal S,
Siddique D,
Hyare H,
Macfarlane R,
Joiner S,
et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet.
2006;
368:
2061–
7.
DOIPubMed Peden A,
McCardle L,
Head MW,
Love S,
Ward HJ,
Cousens SN,
et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia.
2010;
16:
296–
304 .
DOIPubMed Prusiner SB,
Scott MR,
DeArmond SJ,
Cohen FE.
Prion protein biology. Cell.
1998;
93:
337–
48.
DOIPubMed Prusiner SB.
Prions. Proc Natl Acad Sci U S A.
1998;
95:
13363–
83.
DOIPubMed Collinge J.
Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci.
2001;
24:
519–
50.
DOIPubMed Will RG,
Ironside JW,
Zeidler M,
Cousens SN,
Estibeiro K,
Alperovitch A,
et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet.
1996;
347:
921–
5.
DOIPubMed Parchi P,
Castellani R,
Capellari S,
Ghetti B,
Young K,
Chen SG,
et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol.
1996;
39:
767–
78.
DOIPubMed Hill AF,
Joiner S,
Wadsworth JD,
Sidle KC,
Bell JE,
Budka H,
et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain.
2003;
126:
1333–
46.
DOIPubMed Torres JM,
Espinosa JC,
Aguilar-Calvo P,
Herva ME,
Relaño-Ginés A,
Villa-Diaz A,
et al. Elements modulating the prion species barrier and its passage consequences. PLoS One.
2014;
9:
e89722.
DOIPubMed Wadsworth JD, Collinge J. Update on human prion disease. Biochim Biophys Acta. 2007;1772:598–609.
Palmer MS,
Dryden AJ,
Hughes JT,
Collinge J.
Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature.
1991;
352:
340–
2.
DOIPubMed Collinge J,
Palmer MS,
Dryden AJ.
Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet.
1991;
337:
1441–
2.
DOIPubMed Mead S,
Stumpf MP,
Whitfield J,
Beck JA,
Poulter M,
Campbell T,
et al. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science.
2003;
300:
640–
3.
DOIPubMed Baker HE,
Poulter M,
Crow TJ,
Frith CD,
Lofthouse R,
Ridley RM,
et al. Aminoacid polymorphism in human prion protein and age at death in inherited prion disease. Lancet.
1991;
337:
1286.
DOIPubMed Poulter M,
Baker HF,
Frith CD,
Leach M,
Lofthouse R,
Ridley RM,
et al. Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies. Brain.
1992;
115:
675–
85.
DOIPubMed Will RG,
Zeidler M,
Stewart GE,
Macleod MA,
Ironside JW,
Cousens SN,
et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol.
2000;
47:
575–
82.
DOIPubMed Bishop MT,
Diack AB,
Ritchie DL,
Ironside JW,
Will RG,
Manson JC.
Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease. Brain.
2013;
136:
1139–
45.
DOIPubMed Hilton DA,
Ghani AC,
Conyers L,
Edwards P,
McCardle L,
Ritchie D,
et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol.
2004;
203:
733–
9.
DOIPubMed Ironside JW,
Bishop MT,
Connolly K,
Hegazy D,
Lowrie S,
Le Grice M,
et al. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ.
2006;
332:
1186–
8.
DOIPubMed Gill ON,
Spencer Y,
Richard-Loendt A,
Kelly C,
Dabaghian R,
Boyes L,
et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ.
2013;
347(
oct15 5):
f5675.
DOIPubMed Asante EA,
Linehan JM,
Desbruslais M,
Joiner S,
Gowland I,
Wood AL,
et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J.
2002;
21:
6358–
66.
DOIPubMed Wadsworth JD,
Asante EA,
Desbruslais M,
Linehan JM,
Joiner S,
Gowland I,
et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science.
2004;
306:
1793–
6.
DOIPubMed Asante EA,
Linehan JM,
Gowland I,
Joiner S,
Fox K,
Cooper S,
et al. Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proc Natl Acad Sci U S A.
2006;
103:
10759–
64.
DOIPubMed Bishop MT,
Hart P,
Aitchison L,
Baybutt HN,
Plinston C,
Thomson V,
et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol.
2006;
5:
393–
8.
DOIPubMed Takeuchi A,
Kobayashi A,
Ironside JW,
Mohri S,
Kitamoto T.
Characterization of variant Creutzfeldt-Jakob disease prions in prion protein-humanized mice carrying distinct codon 129 genotypes. J Biol Chem.
2013;
288:
21659–
66.
DOIPubMed Padilla D,
Béringue V,
Espinosa JC,
Andreoletti O,
Jaumain E,
Reine F,
et al. Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog.
2011;
7:
e1001319 .
DOIPubMed Espinosa JC,
Herva ME,
Andréoletti O,
Padilla D,
Lacroux C,
Cassard H,
et al. Transgenic mice expressing porcine prion protein resistant to classical scrapie but susceptible to sheep bovine spongiform encephalopathy and atypical scrapie. Emerg Infect Dis.
2009;
15:
1214–
21.
DOIPubMed Castilla J,
Gutiérrez Adán A,
Brun A,
Pintado B,
Ramírez MA,
Parra B,
et al. Early detection of PrPres in BSE-infected bovine PrP transgenic mice. Arch Virol.
2003;
148:
677–
91.
DOIPubMed Castilla J,
Gutiérrez-Adán A,
Brun A,
Doyle D,
Pintado B,
Ramírez MA,
et al. Subclinical bovine spongiform encephalopathy infection in transgenic mice expressing porcine prion protein. J Neurosci.
2004;
24:
5063–
9.
DOIPubMed Aguilar-Calvo P,
Fast C,
Tauscher K,
Espinosa JC,
Groschup MH,
Nadeem M,
et al. Effect of Q211 and K222 PRNP polymorphic variants in the susceptibility of goats to oral infection with goat bovine spongiform encephalopathy. J Infect Dis.
2015;
212:
664–
72.
DOIPubMed Foster JD,
Hope J,
Fraser H.
Transmission of bovine spongiform encephalopathy to sheep and goats. Vet Rec.
1993;
133:
339–
41.
DOIPubMed Goldmann W,
Martin T,
Foster J,
Hughes S,
Smith G,
Hughes K,
et al. Novel polymorphisms in the caprine PrP gene: a codon 142 mutation associated with scrapie incubation period. J Gen Virol.
1996;
77:
2885–
91.
DOIPubMed Eloit M,
Adjou K,
Coulpier M,
Fontaine JJ,
Hamel R,
Lilin T,
et al. BSE agent signatures in a goat. Vet Rec.
2005;
156:
523–
4.
DOIPubMed Cooper JK,
Ladhani K,
Minor PD.
Reference materials for the evaluation of pre-mortem variant Creutzfeldt-Jakob disease diagnostic assays. Vox Sang.
2007;
92:
302–
10.
PubMed Cassard H,
Torres JM,
Lacroux C,
Douet JY,
Benestad SL,
Lantier F,
et al. Evidence for zoonotic potential of ovine scrapie prions. Nat Commun.
2014;
5:
5821.
DOIPubMed Notari S,
Xiao X,
Espinosa JC,
Cohen Y,
Qing L,
Aguilar-Calvo P,
et al. Transmission characteristics of variably protease-sensitive prionopathy. Emerg Infect Dis.
2014;
20:
2006–
14.
DOIPubMed Féraudet C,
Morel N,
Simon S,
Volland H,
Frobert Y,
Créminon C,
et al. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem.
2005;
280:
11247–
58.
DOIPubMed Andréoletti O,
Berthon P,
Levavasseur E,
Marc D,
Lantier F,
Monks E,
et al. Phenotyping of protein-prion (PrPsc)-accumulating cells in lymphoid and neural tissues of naturally scrapie-affected sheep by double-labeling immunohistochemistry. J Histochem Cytochem.
2002;
50:
1357–
70.
DOIPubMed Fraser H,
Dickinson AG.
The sequential development of the brain lesion of scrapie in three strains of mice. J Comp Pathol.
1968;
78:
301–
11.
DOIPubMed Andréoletti O,
Simon S,
Lacroux C,
Morel N,
Tabouret G,
Chabert A,
et al. PrPSc accumulation in myocytes from sheep incubating natural scrapie. Nat Med.
2004;
10:
591–
3.
DOIPubMed Wadsworth JD,
Powell C,
Beck JA,
Joiner S,
Linehan JM,
Brandner S,
et al. Molecular diagnosis of human prion disease. Methods Mol Biol.
2008;
459:
197–
227.
DOIPubMed Vidal E,
Fernández-Borges N,
Pintado B,
Ordóñez M,
Márquez M,
Fondevila D,
et al. Bovine spongiform encephalopathy induces misfolding of alleged prion-resistant species cellular prion protein without altering its pathobiological features. J Neurosci.
2013;
33:
7778–
86.
DOIPubMed de Marco MF,
Linehan J,
Gill ON,
Clewley JP,
Brandner S.
Large-scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. J Pathol.
2010;
222:
380–
7.
DOIPubMed Collinge J.
Medicine. Prion strain mutation and selection. Science.
2010;
328:
1111–
2.
DOIPubMed Douet JY,
Zafar S,
Perret-Liaudet A,
Lacroux C,
Lugan S,
Aron N,
et al. Detection of infectivity in blood of persons with variant and sporadic Creutzfeldt-Jakob disease. Emerg Infect Dis.
2014;
20:
114–
7.
DOIPubMed
Main Article
Page created: August 14, 2017
Page updated: August 14, 2017
Page reviewed: August 14, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.